Add-on biologic a boon for kids with moderate to severe asthma: study
Fortnightly dupilumab with standard therapy leads to rapid and sustained improvements in asthma control for 6-11 year-olds with moderate to severe type 2 asthma, research…
Fortnightly dupilumab with standard therapy leads to rapid and sustained improvements in asthma control for 6-11 year-olds with moderate to severe type 2 asthma, research…
The monoclonal antibody rituximab is just as effective as systemic corticosteroids in treating patients with pemphigoid, but is associated with fewer adverse events, according to…
Need to know: Asthma is a heterogeneous disease characterised by chronic airway inflammation, reversible expiratory airflow limitation and airway hyper-responsiveness.1 × Welcome to AusDoc. Enabling…
New studies provide clarity on the benefits of using the monoclonal antibody vedolizumab plus thiopurines in inflammatory bowel disease.
The rapid development of genomics technologies and their introduction into the clinical setting has resulted in an explosion of knowledge.
Australian dermatologists report a case series of eight patients with mild disease.
A tortoise has inspired an experimental drug-delivery device.
Patients responsive to the IV formulation may find subcutaneous dosing more convenient, expert says.
The biologic has become scarce worldwide because of its use for COVID-19, the manufacturer says.
Researchers recommend COVID-19 vaccines associated with low release of interferon for B cell-depleted patients.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.